Search Results - "Stillman, Ipek Özer"

Estimated Prevalence and Incidence of Dry Eye Disease Based on Coding Analysis of a Large, All-age United States Health Care System by Dana, Reza, Bradley, John L., Guerin, Annie, Pivneva, Irina, Stillman, Ipek Özer, Evans, Amber M., Schaumberg, Debra A.

“…To assess overall prevalence, annual prevalence, and incidence of dry eye disease (DED) in a large, representative population in the United States. Prevalence…”
Get full text

Prevalence of Diagnosed Dry Eye Disease in the United States Among Adults Aged 18 Years and Older by Farrand, Kimberly F., Fridman, Moshe, Stillman, Ipek Özer, Schaumberg, Debra A.

“…To provide current estimates of the prevalence of diagnosed dry eye disease (DED) and associated demographics among US adults aged ≥18 years. Cross-sectional,…”
Get full text

Comorbidities and Prescribed Medications in Patients With or Without Dry Eye Disease: A Population-Based Study by Dana, Reza, Bradley, John L., Guerin, Annie, Pivneva, Irina, Evans, Amber M., Stillman, Ipek Özer

“…To assess the proportion of comorbidities in patients with dry eye disease (DED) compared with matched patients without DED in a comprehensive US population…”
Get full text

Dry eye disease ranking among common reasons for seeking eye care in a large US claims database by Bradley, John L, Özer Stillman, Ipek, Pivneva, Irina, Guerin, Annie, Evans, Amber M, Dana, Reza

“…Dry eye disease (DED) is a complex multifactorial condition of the ocular surface characterized by symptoms of ocular discomfort, irritation, and visual…”
Get full text

Reconstructing the value puzzle in health technology assessment: a pragmatic review to determine which modelling methods can account for additional value elements by Muir, Jeffrey M, Radhakrishnan, Amruta, Freitag, Andreas, Ozer Stillman, Ipek, Sarri, Grammati

“…Health technology assessment (HTA) has traditionally relied on cost-effectiveness analysis (CEA) as a cornerstone of evaluation of new therapies, assessing the…”
Get full text

Meta-analysis for the association between overall survival and progression-free survival in gastrointestinal stromal tumor by Özer-Stillman, Ipek, Strand, Lauren, Chang, Jane, Mohamed, Ateesha F, Tranbarger-Freier, Katherine E

“…Gastrointestinal stromal tumor (GIST) is a relatively rare tumor that is treated with targeted therapies in advanced stages. Randomized clinical trials (RCT)…”
Get full text

Cost-effectiveness analysis of tapentadol immediate release for the treatment of acute pain by Kwong, W. Jacqueline, PharmD, PhD, Özer-Stillman, Ipek, MS, Miller, Jeffrey D., MS, Haber, Noah A., BA, Russell, Mason W., MAPE, Kavanagh, Shane, MSc

“…Abstract Background: Tapentadol immediate-release (IR) tablets are indicated for the treatment of moderate to severe acute pain. In clinical trials, tapentadol…”
Get full text

Health Equity Considerations in Cost-Effectiveness Analysis: Insights from an Umbrella Review by Muir, Jeffrey M, Radhakrishnan, Amruta, Ozer Stillman, Ipek, Sarri, Grammati

“…Cost-effectiveness analyses (CEA) are important in healthcare decision-making and resource allocation; however, expanding the scope of CEAs beyond the…”
Get full text

An economic analysis of axitinib and sorafenib for second-line treatment of cytokine-refractory patients with advanced renal cell carcinoma in the United States (US) by Özer-Stillman, Ipek, Ambavane, Apoorva, Cislo, Paul

“…Abstract only e15601 Background: Cytokines are a first-line treatment option for a subset of advanced RCC patients in the US. After progression on cytokines,…”
Get full text

The relationship between overall survival (OS) and progression-free survival (PFS) in gastrointestinal stromal tumor (GIST) by Özer Stillman, Ipek, Strand, Lauren N., Chang, Jane, Mohamed, Ateesha F., Fahrbach, Kyle, Tranbarger Freier, Katherine E.

“…Abstract only…”
Get full text

Cost-effectiveness of regorafenib for pretreated metastatic colorectal cancer patients in the United States by Seal, Brian S., Özer-Stillman, Ipek, Whalen, John, Ambavane, Apoorva, Yaldo, Avin, Pawar, Vivek

“…Abstract only 578 Background: There is an unmet need for treatments that provide a survival benefit for patients with heavily pretreated metastatic colorectal…”
Get full text

Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US by Saint-Laurent Thibault, Catherine, Özer Stillman, Ipek, Chen, Stephanie, Getsios, Denis, Proskorovsky, Irina, Hernandez, Luis, Dixit, Shailja

“…This study evaluates the cost-effectiveness of memantine extended release (ER) as an add-on therapy to acetylcholinesterase inhibitor (AChEI) [combination…”
Get more information

P2‐320: COST‐EFFECTIVENESS OF MEMANTINE EXTENDED RELEASE FOR TREATMENT OF MODERATE‐TO‐SEVERE ALZHEIMER'S DISEASE IN THE UNITED STATES by Saint‐Laurent Thibault, Catherine, Stillman, Ipek Özer, Chen, Stephanie, Getsios, Denis, Proskorovsky, Irina, Hernandez, Luis, Dixit, Shailja

Get full text

COST-EFFECTIVENESS OF MEMANTINE EXTENDED RELEASE FOR TREATMENT OF MODERATE-TO-SEVERE ALZHEIMER'S DISEASE IN THE UNITED STATES by Saint-Laurent Thibault, Catherine, Stillman, Ipek Özer, Chen, Stephanie, Getsios, Denis, Proskorovsky, Irina, Hernandez, Luis, Dixit, Shailja

Get full text

Abstract 372: Health Outcomes Associated With Triple Antiplatelet Therapy for the Secondary Prevention of Atherothrombotic Events by Ozer-Stillman, Ipek, Whalen, John D, Bash, Lori D, Oguz, Mustafa, Du, Mark, Singhal, Puneet K, Davies, Glenn M

“…Abstract only Vorapaxar is a protease-activated receptor-1 (PAR-1) antagonist indicated for the reduction of atherothrombotic cardiovascular (CV) events in…”
Get full text

A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction by Whalen, John D., Davies, Glenn, Du, Mark, Oguz, Mustafa, Bash, Lori D., Ozer-Stillman, Ipek

“…Background The TRA 2°P-TIMI 50 trial showed the addition of vorapaxar to standard care (SC) antiplatelet therapy reduced the combined risk of death, myocardial…”
Get full text

Cost-effectiveness analysis of bendamustine plus rituximab versus CHOP-R in treatment-naive patients with mantle cell (MCL) and indolent lymphomas (IL) by Su, Wayne, Quon, Peter, Whalen, John, Ranganathan, Gayatri, Wronski, Samantha, Mwamburi, Mkaya, Knopf, Kevin B., Sterchele, James A., Salvador, Christopher G., Ozer Stillman, Ipek, Kadambi, Ananth

“…Abstract only 6553 Background: To assess the cost-effectiveness of bendamustine plus rituximab (B-R) vs cyclophosphamide, doxorubicin, vincristine, prednisone,…”
Get full text